J Korean Med Sci.  2004 Feb;19(1):137-141. 10.3346/jkms.2004.19.1.137.

Adult-onset Still's Disease with Disseminated Intravascular Coagulation and Multiple Organ Dysfunctions Dramatically Treated with Cyclosporine A

• Park JH
• Bae JH
• Choi YS
• Lee HS
• Jun JB
• Jung S
• Yoo DH
• Bae SC
• Kim TH

• KMID: 1785709
• DOI: http://doi.org/10.3346/jkms.2004.19.1.137

Abstract

Severe systemic manifestations of adult onset Still's disease (AOSD) are often fatal and occasionally related to hemophagocytic syndrome (HS). We describe the case of a 49-yr-old woman with AOSD presenting with non-remitting high fever, confusion, jaundice, hepatosplenomegaly, serositis, azotemia, pancytopenia, coagulopathy with disseminated intravascular coagulation (DIC), hyperferritinemia, acute acalculous cholecystitis and ileocolitis noted in computed tomographic images. The patient had a history of herpes zoster developed prior to the admission, but there is no history of diarrhea or abdominal pain. Although bone marrow examination was not performed due to hemorrhagic diathesis, we suspected AOSD-associated HS on the basis of clinical course without detectable infectious agents in cultures or serologic studies. Intravenous immunoglobulin, pulse methylprednisolone, oral cyclosporine A (CsA) and ceftriaxone brought about transient improvement of fever and confusion, but the disease progressed. After increasing CsA dose, all previously mentioned abnormalities disappeared rapidly. Accordingly, we believe that DIC and multiple organ dysfunctions might have been the complications of HS but not that of sepsis, and that CsA can be used as a first-line therapy in case of life-threatening situations.

Keyword

Still's Disease, Adult-onset; Hemophagocytic Syndrome; Cyclosporins

MeSH Terms

Colon/radiography
Cyclosporine/*therapeutic use
Female
Human
Immunosuppressive Agents/*therapeutic use
Middle Aged
*Multiple Organ Failure
Still's Disease, Adult-Onset/*diagnosis/*pathology
Time Factors
Tomography, X-Ray Computed

Figure

• 

  Fig. 1 Computed tomographic findings of abdomen appear acute acalculous cholecystitis and ileocolitis. (A) A thickened wall of gall bladder with pericholecytic fluid collection, (B) An unenhanced wall thickenings of cecum and terminal ileum.

• 

  Fig. 2 Clinical course and treatment of this patient. FFP, fresh frozen plasma; PC, platelet concentrate; PRC, packed red cell; PSL, prednisolone; IVIG, intravenous immunoglobulin; ND, not done.

Reference

1. Ohta A, Yamaguchi M, Kaneoka H, Nagayoshi T, Hiida M. Adult Still's disease: review of 228 cases from the literature. J Rheumatol. 1987. 14:1139–1146.

2. Coffernils M, Soupart A, Pradier O, Feremans W, Neve P, Decaux G. Hyperferritinemia in adult onset Still's disease and the hemophagocystic syndrome. J Rheumatol. 1992. 19:1425–1427.

3. Kumakura S, Ishikura H, Munemasa S, Adachi T, Murakawa Y, Kobayashi S. Adult onset Still's disease associated hemophagocytosis. J Rheumatol. 1997. 24:1645–1648.

4. Takeshita A, Takeuchi T, Nakagawa A, Tsuda Y, Fukuda A, Nariyama K, Shibayama Y. Adult onset Still's disease with hemophagocytic syndrome and severe liver dysfunction. Hepatol Res. 2000. 17:139–144.

5. Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T, Akizuki M. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992. 19:424–430.

6. Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol. 1997. 66:135–151.

7. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol. 2002. 14:548–552.

8. Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, Spaeth PJ, Neftel KA. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol. 2001. 68:4–10.

9. Emmenegger U, Reimers A, Frey U, Fux C, Bihl F, Semela D, Cottagnoud P, Cerny A, Spaeth PJ, Neftel KA. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation. Swiss Med Wkly. 2002. 132:230–236.

10. Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive hemophagocytic syndrome in children with inflammatory disorders: a retrospective study of 24 patients. Rheumatology. 2001. 40:1285–1292.

11. Henter JI, Arico M, Elinder G, Imashuku S, Janka G. Familial hemophagocytic lymphohistiocytosis: primary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998. 12:417–433.

12. Ost A, Nilsson-Ardnor S, Henter JI. Autopsy findings in 27 children with haemophagocytic lymphohistiocytosis. Histopathology. 1998. 32:310–316.

13. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection and malignancy associated hemophagocytic syndromes: secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998. 12:435–444.

14. Miyahara M, Sano M, Shibata K, Matsuzaki M, Ibaraki K, Shimamoto Y, Tokunaga O. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics. Ann Hematol. 2000. 79:378–388.

15. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis. 2000. 6:601–608.

16. Otero Anton E, Lado Abeal J, Losada Arias E, Barrio Gomez E. Enterocolitis and acute non-calculous cholecystitis caused by Salmonella enteritidis. Med Clin (Barc). 1996. 106:155–156.

17. Kanaji S, Okuma K, Tokumitsu Y, Yoshizawa S, Nakamura M, Niho Y. Hemophagocytic syndrome associated with fulminant ulcerative colitis and presumed acute pancreatitis. Am J Gastroenterol. 1998. 93:1956–1959.

18. Maclachlan D, Tyndall A. Acute hepatitis in adult Still's disease apparently resulting from oral iron substitution: a case report. Clin Rheumatol. 2000. 19:222–225.

19. Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001. 28:2120–2124.

20. Ravelli A, Viola S, De Benedetti F, Magni-Manzoni S, Tzialla C, Martini A. Dramatic efficacy of cyclosporine A in macrophage activation syndrome. Clin Exp Rheumatol. 2001. 19:108.

21. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996. 129:750–754.

22. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporine A and FK506. Immunol Today. 1992. 13:136–142.

23. Garcia JE, Lopez AM, de Cabo MR, Rodriguez FM, Losada JP, Sarmiento RG, Lopez AJ, Arellano JL. Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level. Mediators Inflamm. 1999. 8:253–259.

24. Garcia JE, de Cabo MR, Rodriguez FM, Losada JP, Lopez AJ, Arellano JL. Effect of cyclosporin A on inflammatory cytokine production by U937 monocyte-like cells. Mediators Inflamm. 2000. 9:169–174.

25. Attur MG, Patel R, Thakker G, Vyas P, Levartovsky D, Patel P, Naqvi S, Raza R, Patel K, Abramson D, Bruno G, Abramson SB, Amin AR. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res. 2000. 49:20–26.

26. Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW, Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation. 1999. 68:1255–1263.